FIELD: biotechnology; medicine.
SUBSTANCE: invention refers to biotechnology, virology, medicine. Described is a strain of a recombinant pseudo adenoviral particle based on human adenovirus genome 5 of serotype Ad5-tetOFF-E3-HA125 for producing anti-influenza immunogenic preparations, carrying a consensus gene of haemagglutinin virus of influenza A virus subtypes H1, H2, H5 enriched with B and T-cell epitopes of influenza virus with nucleotide sequence SEQ ID NO: 2, wherein the influenza A haemagglutinin consensus sequence gene codes the amino acid sequence SEQ ID NO: 1. Method for preparing a haemagglutinin consensus sequence with the nucleotide sequence SEQ ID NO: 2. Also described is an immunogenic preparation containing a strain of a recombinant pseudo adenoviral particle based on human adenovirus genome 5 of a serotype according to claim 1. for preventing influenza A, caused by subtypes H1, H2 and H5, containing per dose: recombinant pseudo adenoviral particle Ad5-tetOFF-E3-HA125 - 107-109 actuation components. and a pharmaceutically acceptable buffer solution - up to 0.5 ml.
EFFECT: invention extends the range of agents for preventing influenza A.
3 cl, 8 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PSEUDO-ADENOVIRUS PARTICLE BASED ON GENOME OF HUMAN ADENOVIRUS OF SEROTYPE 5, PRODUCING INFLUENZA HEMAGGLUTININ OF STRAIN A/Brisbane/59/2007(H1N1) AND METHOD OF ITS USE | 2012 |
|
RU2523599C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 5 SEROTYPE, INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A VIRUSES OF SUBTYPE H1, AND A PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2802753C1 |
| ANTIVIRAL SIMILAR MINI-ANTIBODY, NUCLEOTIDE SEQUENCE, EXPRESSING RECOMBINANT VIRAL VECTOR, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION OR THERAPY OF INFLUENZA TYPE A | 2013 |
|
RU2536956C1 |
| RECOMBINANT PSEUDO ADENOVIRAL PARTICLE BASED ON HUMAN BEING ADENOVIRUS GENOME OF 5-TH SEROTYPE FOR INDUCTION OF SPECIFIC IMMUNITY TO INFLUENZA VIRUS A OF H1N1 SUBTYPE AND METHOD OF ITS USE AS COMPONENT FOR VACCINE PRODUCTION | 2012 |
|
RU2507257C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS SEROTYPE 5 INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A SUBTYPE H3 VIRUSES AND PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2814189C1 |
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| SINGLE-DOMAIN ANTIBODY FOR NEUTRALIZING VIRUSES AND ITS MODIFICATION, AND A METHOD FOR THEIR USE FOR EMERGENCY PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS | 2021 |
|
RU2777073C1 |
| RECOMBINANT VIRUS-LIKE PARTICLES (VLP) USING BOVINE IMMUNODEFICIENCY VIRUS GROUP-SPECIFIC ANTIGEN (GAG) PROTEIN | 2016 |
|
RU2734118C2 |
| BROAD-SPECTRUM M2 PROTEIN ECTODOMAIN AVIAN INFLUENZA TYPE A VACCINE | 2014 |
|
RU2571944C1 |
